• The combination of ATRA and LD-RTX could achieve an 80% OR rate and a 61% SR rate.

  • The ATRA plus LD-RTX regimen is a promising treatment option for corticosteroid-resistant or relapsed ITP.

The study aimed to compare the efficacy and safety of all-trans retinoic acid (ATRA) plus low-dose rituximab (LD-RTX) with LD-RTX monotherapy in corticosteroid-resistant or relapsed immune thrombocytopenia (ITP) patients. Recruited patients were randomized at a ratio of 2:1 into 2 groups: 112 patients received LD-RTX plus ATRA, and 56 patients received LD-RTX monotherapy. Overall response (OR), defined as achieving a platelet count of ≥30 × 109/L confirmed on ≥2 separate occasions (≥7 days apart), at least a doubling of the baseline platelet count without any other ITP-specific treatment, and the absence of bleeding within 1 year after enrollment, was observed in more patients in the LD-RTX plus ATRA group (80%) than in the LD-RTX monotherapy group (59%) (between-group difference, 0.22; 95% CI, 0.07-0.36). Sustained response (SR), defined as maintenance of a platelet count >30 × 109/L, an absence of bleeding, and no requirement for any other ITP-specific treatment for 6 consecutive months after achievement of OR during 1 year following enrollment, was achieved by 68 (61%) patients in the combination group and 23 (41%) patients in the monotherapy group (between-group difference, 0.20; 95% CI, 0.04-0.35). The 2 most common adverse events (AEs) for the combination group were dry skin and headache or dizziness. Our findings demonstrated that ATRA plus LD-RTX significantly increased the overall and sustained response, indicating a promising treatment option for corticosteroid-resistant or relapsed adult ITP. This study is registered at www.clinicaltrials.gov as #NCT03304288.

1.
Cooper
N
,
Ghanima
W
.
Immune thrombocytopenia
.
N Engl J Med.
2019
;
381
(
10
):
945
-
955
.
2.
Berchtold
P
,
Wenger
M
.
Autoantibodies against platelet glycoproteins in autoimmune thrombocytopenic purpura: their clinical significance and response to treatment
.
Blood.
1993
;
81
(
5
):
1246
-
1250
.
3.
McMillan
R
,
Wang
L
,
Tomer
A
,
Nichol
J
,
Pistillo
J
.
Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP
.
Blood.
2004
;
103
(
4
):
1364
-
1369
.
4.
Olsson
B
,
Andersson
PO
,
Jernås
M
, et al
.
T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura
.
Nat Med.
2003
;
9
(
9
):
1123
-
1124
.
5.
Provan
D
,
Arnold
DM
,
Bussel
JB
, et al
.
Updated international consensus report on the investigation and management of primary immune thrombocytopenia
.
Blood Adv.
2019
;
3
(
22
):
3780
-
3817
.
6.
Neunert
C
,
Terrell
DR
,
Arnold
DM
, et al
.
American Society of Hematology 2019 guidelines for immune thrombocytopenia
.
Blood Adv.
2019
;
3
(
23
):
3829
-
3866
.
7.
Stasi
R
,
Del Poeta
G
,
Stipa
E
, et al
.
Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura
.
Blood.
2007
;
110
(
8
):
2924
-
2930
.
8.
Stasi
R
,
Cooper
N
,
Del Poeta
G
, et al
.
Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab
.
Blood.
2008
;
112
(
4
):
1147
-
1150
.
9.
Stasi
R
,
Pagano
A
,
Stipa
E
,
Amadori
S
.
Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura
.
Blood.
2001
;
98
(
4
):
952
-
957
.
10.
Zaja
F
,
Volpetti
S
,
Chiozzotto
M
, et al
.
Long-term follow-up analysis after rituximab salvage therapy in adult patients with immune thrombocytopenia
.
Am J Hematol.
2012
;
87
(
9
):
886
-
889
.
11.
Patel
VL
,
Mahévas
M
,
Lee
SY
, et al
.
Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia
.
Blood.
2012
;
119
(
25
):
5989
-
5995
.
12.
Li
Y
,
Shi
Y
,
He
Z
, et al
.
The efficacy and safety of low-dose rituximab in immune thrombocytopenia: a systematic review and meta-analysis
.
Platelets.
2019
;
30
(
6
):
690
-
697
.
13.
Chaturvedi
S
,
Arnold
DM
,
McCrae
KR
.
Splenectomy for immune thrombocytopenia: down but not out
.
Blood.
2018
;
131
(
11
):
1172
-
1182
.
14.
Ghanima
W
,
Khelif
A
,
Waage
A
, et al;
RITP study group
.
Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial
.
Lancet.
2015
;
385
(
9978
):
1653
-
1661
.
15.
Ferraro
AJ
,
Drayson
MT
,
Savage
CO
,
MacLennan
IC
.
Levels of autoantibodies, unlike antibodies to all extrinsic antigen groups, fall following B cell depletion with Rituximab
.
Eur J Immunol.
2008
;
38
(
1
):
292
-
298
.
16.
Looney
RJ
,
Anolik
JH
,
Campbell
D
, et al
.
B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab
.
Arthritis Rheum.
2004
;
50
(
8
):
2580
-
2589
.
17.
Avilés
A
,
Talavera
A
,
Díaz-Maqueo
JC
,
García
EL
,
Cleto
S
,
Neri
N
.
Evaluation on a six-dose treatment of anti CD 20 monoclonal antibody in patients with refractory follicular lymphoma
.
Cancer Biother Radiopharm.
2001
;
16
(
2
):
159
-
162
.
18.
Avilés
A
,
León
MI
,
Díaz-Maqueo
JC
,
García
EL
,
Cleto
S
,
Neri
N
.
Rituximab in the treatment of refractory follicular lymphoma -- six doses are better than four
.
J Hematother Stem Cell Res.
2001
;
10
(
2
):
313
-
316
.
19.
Vital
EM
,
Dass
S
,
Buch
MH
,
Rawstron
AC
,
Emery
P
.
An extra dose of rituximab improves clinical response in rheumatoid arthritis patients with initial incomplete B cell depletion: a randomised controlled trial
.
Ann Rheum Dis.
2014
;
74
(
6
):
1195
-
1201
.
20.
Huang
ME
,
Ye
YC
,
Chen
SR
, et al
.
Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia
.
Blood.
1988
;
72
(
2
):
567
-
572
.
21.
Breitman
TR
,
Collins
SJ
,
Keene
BR
.
Terminal differentiation of human promyelocytic leukemic cells in primary culture in response to retinoic acid
.
Blood.
1981
;
57
(
6
):
1000
-
1004
.
22.
Xu
LL
,
Fu
HX
,
Zhang
JM
, et al
.
Impaired function of bone marrow mesenchymal stem cells from immune thrombocytopenia patients in inducing regulatory dendritic cell differentiation through the notch-1/jagged-1 signaling pathway
.
Stem Cells Dev.
2017
;
26
(
22
):
1648
-
1661
.
23.
Feng
Q
,
Xu
M
,
Yu
YY
, et al
.
High-dose dexamethasone or all-trans-retinoic acid restores the balance of macrophages towards M2 in immune thrombocytopenia
.
J Thromb Haemost.
2017
;
15
(
9
):
1845
-
1858
.
24.
He
Y
,
Xu
LL
,
Feng
FE
, et al
.
Mesenchymal stem cell deficiency influences megakaryocytopoiesis through the TNFAIP3/NF-κB/SMAD pathway in patients with immune thrombocytopenia
.
Br J Haematol.
2018
;
180
(
3
):
395
-
411
.
25.
Zhu
X
,
Wang
Y
,
Jiang
Q
, et al
.
All-trans retinoic acid protects mesenchymal stem cells from immune thrombocytopenia by regulating the complement-interleukin-1β loop
.
Haematologica.
2019
;
104
(
8
):
1661
-
1675
.
26.
Feng
FE
,
Feng
R
,
Wang
M
, et al
.
Oral all-trans retinoic acid plus danazol versus danazol as second-line treatment in adults with primary immune thrombocytopenia: a multicentre, randomised, open-label, phase 2 trial
.
Lancet Haematol.
2017
;
4
(
10
):
e487
-
e496
.
27.
Dai
L
,
Zhang
R
,
Wang
Z
, et al
.
Efficacy of immunomodulatory therapy with all-trans retinoid acid in adult patients with chronic immune thrombocytopenia
.
Thromb Res.
2016
;
140
:
73
-
80
.
28.
Neunert
C
,
Lim
W
,
Crowther
M
,
Cohen
A
,
Solberg
L
Jr
,
Crowther
MA
;
American Society of Hematology
.
The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia
.
Blood.
2011
;
117
(
16
):
4190
-
4207
.
29.
Thrombosis and Hemostasis Group, Hematology Society, Chinese Medical Association
.
Consensus of Chinese experts on diagnosis and treatment of adult primary immune thrombocytopenia (version 2016) [in Chinese]
.
Zhonghua Xue Ye Xue Za Zhi.
2016
;
37
(
2
):
89
-
93
.
30.
Fogarty
PF
,
Tarantino
MD
,
Brainsky
A
,
Signorovitch
J
,
Grotzinger
KM
.
Selective validation of the WHO Bleeding Scale in patients with chronic immune thrombocytopenia
.
Curr Med Res Opin.
2011
;
28
(
1
):
79
-
87
.
31.
Zaja
F
,
Baccarani
M
,
Mazza
P
, et al
.
Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia
.
Blood.
2010
;
115
(
14
):
2755
-
2762
.
32.
Wei
Y
,
Ji
XB
,
Wang
YW
, et al
.
High-dose dexamethasone vs prednisone for treatment of adult immune thrombocytopenia: a prospective multicenter randomized trial
.
Blood.
2016
;
127
(
3
):
296
-
302, quiz 370
.
33.
Zaja
F
,
Vianelli
N
,
Volpetti
S
, et al
.
Low-dose rituximab in adult patients with primary immune thrombocytopenia
.
Eur J Haematol.
2010
;
85
(
4
):
329
-
334
.
34.
Zhou
H
,
Xu
M
,
Qin
P
, et al
.
A multicenter randomized open-label study of rituximab plus rhTPO vs rituximab in corticosteroid-resistant or relapsed ITP
.
Blood.
2015
;
125
(
10
):
1541
-
1547
.
35.
Mazzucconi
MG
,
Fazi
P
,
Bernasconi
S
, et al;
Gruppo Italiano Malattie EMatologiche dell’Adulto (GIMEMA) Thrombocytopenia Working Party
.
Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience
.
Blood.
2006
;
109
(
4
):
1401
-
1407
.
36.
National Cancer Institute
.
CTCAE version 5.0
. Available at: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Referen ce_8.5x11.pdf. Accessed November 27,
2017
37.
Sui
T
,
Zhang
L
,
Zhou
ZP
,
Xue
F
,
Ge
J
,
Yang
RC
.
Efficacy and safety of two different low-dose rituximab regimens for Chinese adult patients with immune thrombocytopenia [in Chinese]
.
Zhonghua Xue Ye Xue Za Zhi.
2011
;
32
(
9
):
583
-
586
.
38.
Fernandez-Martinez
M
,
Esterlich
E
,
Vallano
A
,
Danés Carreras
I
,
Agustí
A
.
Off-label uses of low-dose rituximab: a systematic review of the literature
.
Clin Ther.
2015
;
37
(
8
):
e117
-
e118
.
39.
Li
Y
,
Wang
XM
,
Mao
M
, et al
.
Clinical efficacy of lower dose rituximab for chronic refractory immune thrombocytopenic purpura [in Chinese]
.
Zhonghua Xue Ye Xue Za Zhi.
2012
;
33
(
3
):
204
-
206
.
40.
Zhang
C
,
Liu
HF
,
Chen
XH
, et al
.
Is splenectomy necessary for immune thrombocytopenic purpura? The role of rituximab in patients with corticosteroid resistance in a single-center experience
.
Clin Ther.
2014
;
36
(
3
):
385
-
388
.
41.
Provan
D
,
Butler
T
,
Evangelista
ML
,
Amadori
S
,
Newland
AC
,
Stasi
R
.
Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults
.
Haematologica.
2007
;
92
(
12
):
1695
-
1698
.
42.
Kapoor
R
,
Kumar
R
,
Mahapatra
M
,
Pati
HP
Pramanik
SK
.
Low dose rituximab in chronic ITP: still an option in resource limited settings
.
Indian J Hematol Blood Transfus.
2016
;
33
(
4
):
568
-
573
.
43.
Raza
K MP
,
Quinn
J
,
Thornton
P
.
An experience with low dose rituximab for the treatment of patients with chronic immune thrombocytopenic purpura: aretrospective analysis of six patients
.
Haematological.
2012
;
97
(
683
).
44.
Khellaf
M
,
Charles-Nelson
A
,
Fain
O
, et al
.
Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients
.
Blood.
2014
;
124
(
22
):
3228
-
3236
.
45.
Godeau
B
,
Porcher
R
,
Fain
O
, et al
.
Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study
.
Blood.
2008
;
112
(
4
):
999
-
1004
.
46.
Oved
JH
,
Lee
CSY
,
Bussel
JB
.
Treatment of children with persistent and chronic idiopathic thrombocytopenic purpura: 4 infusions of rituximab and three 4-day cycles of dexamethasone
.
J Pediatr.
2017
;
191
:
225
-
231
.
47
Miltiadous
O
,
Hou
M
,
Bussel
JB
.
Identifying and treating refractory ITP: difficulty in diagnosis and role of combination treatment
.
Blood.
2020
;
135
(
7
):
472
-
490
.
48.
Calado
RT
,
Clé
DV
.
Treatment of inherited bone marrow failure syndromes beyond transplantation
.
Hematology Am Soc Hematol Educ Program.
2017
;
2017
:
96
-
101
.
49.
Jiao
L
,
Xiang
Y
,
Li
S
,
Zhang
F
,
Ruan
X
,
Guo
S
.
Efficacy of low dose rituximab in treatment-resistant CIDP with antibodies against NF-155
.
J Neuroimmunol.
2020
;
345
:
577280
.
50.
Lee
MS
,
Kim
WC
.
Intracranial hemorrhage associated with idiopathic thrombocytopenic purpura: report of seven patients and a meta-analysis
.
Neurology.
1998
;
50
(
4
):
1160
-
1163
.
51.
Cines
DB
,
Bussel
JB
.
How I treat idiopathic thrombocytopenic purpura (ITP)
.
Blood.
2005
;
106
(
7
):
2244
-
2251
.
52.
Puavilai
T
,
Thadanipon
K
,
Rattanasiri
S
, et al
.
Treatment efficacy for adult persistent immune thrombocytopenia: a systematic review and network meta-analysis
.
Br J Haematol.
2019
;
188
(
3
):
450
-
459
.
You do not currently have access to this content.

Sign in via your Institution

Sign In